DLH Wins Renewal of Clinical Support to NIH-Funded AIDS Clinical Trials Group (ACTG)
January 11 2021 - 8:00AM
DLH Holdings Corp. (NASDAQ: DLHC) (“DLH”
or the “Company”), a leading provider of innovative
healthcare services and solutions to federal agencies, today
announced that it has been awarded a contract to continue operating
the AIDS Clinical Trials Group’s (ACTG) Network Coordinating Center
(NCC). ACTG, which is funded by the National Institutes of Health,
is the world’s largest and longest running HIV clinical trials
network, conducting research to improve the treatment of HIV, its
co-infections, and its comorbidities. The NCC collaborates with
ACTG leadership to provide technical, scientific, and
administrative support.
DLH’s award under this contract has an estimated
total value of up to $42 million (one base year and six option
years). This contract is a subaward to DLH from the ACTG Leadership
and Operations Center at the University of California, Los Angeles,
which has been funded for the next seven years by NIH’s National
Institute of Allergy and Infectious Diseases (NIAID) and
collaborating NIH institutes. ACTG was the first clinical trials
network to focus on HIV and currently has sites in 15 countries.
ACTG often carries out other epidemiological studies and, in 2020,
implemented the ACTIV-2 study, a trial to identify effective
treatments for early COVID-19.
“DLH is honored to continue its longstanding
support of ACTG in its mission to cure HIV and reduce the burden of
other emerging infectious diseases,” said DLH President and Chief
Executive Officer Zach Parker. “This work combines many of our
strengths as a company -- managing a consortium of partners,
leveraging clinical trials expertise, and developing innovative
technology -- all in the service of our customer’s vital public
health mission.”
“DLH values its relationship with ACTG and is
deeply proud of our sustained commitment to this critical public
health initiative,” added Jeanine Christian, President of DLH’s
Public Health & Scientific Research operating unit.
DLH has managed the NCC since 1987. In this
role, DLH staff facilitate the implementation of the network’s
scientific research agenda, providing technical and clinical
support to ACTG and its community advocates. Responsibilities
include protocol development and implementation, site capacity
development, and facilitation of network consortium partner
collaboration and communications. DLH developed and customized a
secure information management system to support the network’s
governance, administrative and scientific structure. Named the
‘Network Management Information System’ (MIS), this innovative,
web-based information management system was uniquely adapted to
support the work of the NCC.
About DLHDLH (NASDAQ:DLHC) is a
comprehensive health solutions and services provider that delivers
a full range of technology-enabled health services across various
civilian agencies, the military health system, and the Veterans
Administration. The Company’s services range from providing virtual
pharmacy health consultation for CHAMPVA beneficiaries to veteran
pharmacy fulfillment and medical logistics; conducting scientific
research and clinical trials toward disease prevention and health
promotion; performing medical research and development and
enhancing health information technology systems (including
telemedicine and electronic health records); and evaluating policy
deployment and compliance with applicable protocols and guidelines,
with a goal of enhancing the Company’s readiness posture while
providing safe, effective and integrated solutions and services to
the public, armed service members, and veterans who have secured
this nation’s freedom. DLH has over 2,200 employees serving
numerous government agencies. For more information, visit the
corporate website at www.dlhcorp.com
Safe Harbor Statement under the Private
Securities Litigation Reform Act of 1995:This press
release may contain forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These
statements relate to future events or DLH`s future financial
performance. Any statements that refer to expectations,
projections or other characterizations of future events or
circumstances or that are not statements of historical fact
(including without limitation statements to the effect that the
Company or its management “believes”, “expects”, “anticipates”,
“plans”, “intends” and similar expressions) should be considered
forward looking statements that involve risks and uncertainties
which could cause actual events or DLH’s actual results to differ
materially from those indicated by the forward-looking statements.
Forward-looking statements in this release include, among others,
statements regarding estimates of future revenues, operating
income, earnings and cash flow. These statements reflect our belief
and assumptions as to future events that may not prove to be
accurate. Our actual results may differ materially from such
forward-looking statements made in this release due to a variety of
factors, including: the outbreak of the novel coronavirus
(“COVID-19”), including the measures to reduce its spread, and its
impact on the economy and demand for our services, are uncertain,
cannot be predicted, and may precipitate or exacerbate other risks
and uncertainties; the risk that we will not realize the
anticipated benefits of the IBA or any future acquisition; the
challenges of managing larger and more widespread operations
resulting from the acquisition; contract awards in connection with
re-competes for present business and/or competition for new
business; compliance with new bank financial and other covenants;
changes in client budgetary priorities; government contract
procurement (such as bid protest, small business set asides, loss
of work due to organizational conflicts of interest, etc.) and
termination risks; the ability to successfully integrate the
operations our recent acquisition and any of future acquisitions;
and other risks described in our SEC filings. For a discussion of
such risks and uncertainties which could cause actual results to
differ from those contained in the forward-looking statements, see
“Risk Factors” in the Company’s periodic reports filed with the
SEC, including our Annual Report on Form 10-K for the fiscal year
ended September 30, 2020, as well as subsequent reports filed
thereafter. The forward-looking statements contained herein are not
historical facts, but rather are based on current expectations,
estimates, assumptions and projections about our industry and
business. Such forward-looking statements are made as
of the date hereof and may become outdated over time. The Company
does not assume any responsibility for updating forward-looking
statements, except as may be required by law.
DLH Investor Relations |
Contact: Chris Witty |
Phone: 646-438-9385 |
Email: cwitty@darrowir.com |
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
DLH (NASDAQ:DLHC)
Historical Stock Chart
From Sep 2023 to Sep 2024